GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Price-to-Owner-Earnings

Chimeric Therapeutics (ASX:CHM) Price-to-Owner-Earnings : (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Price-to-Owner-Earnings?

As of today (2024-12-13), Chimeric Therapeutics's share price is A$0.006. Chimeric Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Chimeric Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ASX:CHM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-13), Chimeric Therapeutics's share price is A$0.006. Chimeric Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02. Therefore, Chimeric Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-13), Chimeric Therapeutics's share price is A$0.006. Chimeric Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.02. Therefore, Chimeric Therapeutics's PE Ratio without NRI for today is At Loss.


Chimeric Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Chimeric Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Price-to-Owner-Earnings Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Price-to-Owner-Earnings
- - - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of Chimeric Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Chimeric Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimeric Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Price-to-Owner-Earnings falls into.



Chimeric Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chimeric Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.006/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics  (ASX:CHM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Chimeric Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

No Headlines